Whereas an association between expression of survivin and disease-specific survival (DSS) did not become evident (HR 2.08; 95% CI: 0.86–5.03; p = 0.10; I2 = 33%) (Figure 4A), the pooled HR of 8 studies that evaluated the association between survivin and DFS demonstrated the prognostic relevance of survivin expression in lung cancer patients, despite heterogeneity (HR 1.62; 95% CI: 1.14–2.29; p = 0.006; I2 = 63%) (Figure 4B). This evidence concerns the gene BIRC5 and lung carcinoma.